Montreal Heart Institute needs participants for COVID-19 clinical trial
Apr 23, 2020, 4:07 PM | Updated: Oct 8, 2024, 6:47 am
In today’s Coronavirus Medical Update, are you familiar with joint pain and stiffness, maybe arthritis that happens every so often in the big toe? Yes, gout.
Colchicine is the drug that’s used to treat gout, and is a part of a clinical trial that’s led by Jean-Claude Tardif from the Montreal Heart Institute. He has teamed up with the University of California San Francisco as well as New York University for this clinical trial.
It’s open to 6,000 patients internationally, so anyone from the U.S., Canada, and pretty much across the world who has tested positive for COVID-19 can be a part of this study with the drug colchicine. However, there’s a caveat. This is a placebo trial, so either you get the drug, or you don’t get the drug and you get a placebo.
How to listen to KIRO Radio during stay-at-home order
If you want to learn more about how you can get involved with this COVID-19 clinical trial, tune in to KIRO Radio on the :40s for the Coronavirus Medical Update with Tracy Taylor.
